102460 — Reyon Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapSucker Stock

Market Cap
KR₩230bn
Enterprise Value
KR₩436bn
Revenue
KR₩148bn

Annual income statement for Reyon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	130,034	142,801	154,039	151,071	148,300
Cost of Revenue
Gross Profit	72,585	79,438	81,728	78,899	72,785
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	125,893	139,062	144,406	147,038	148,494
Operating Profit	4,141	3,739	9,633	4,034	-194
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,368	5,845	6,894	4,032	5,163
Provision for Income Taxes
Net Income After Taxes	3,844	5,537	7,434	3,583	4,151
Minority Interest
Net Income Before Extraordinary Items
Net Income	3,844	5,537	7,434	3,583	4,151
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,844	5,412	7,359	3,583	4,151
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	221	313	402	195	240
Dividends per Share